Stay updated with breaking news from Markus Renschler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Mark Foundation for Cancer Research, a leading nonprofit dedicated to advancing research that transforms the prevention, diagnosis, and treatment of cancer, proudly announces the appointment of new members to its Scientific Advisory and Industry Advisory Committees.
The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer.
Cyteir Therapeutics, Inc. today announced that it is discontinuing all development of CYT-0851, its investigational monocarboxylate transporter inhibitor, and that Cyteir’s Board of Directors...
- CYT-0851 has demonstrated early activity in combination with capecitabine or gemcitabine in advanced solid tumors and a generally well tolerated safety profile in a heavily pretreated population of... | June 3, 2023
/PRNewswire/ -- The Association of Bioscience Financial Officers (ABFO) has announced the return of its national conference to San Francisco. Set for May 15-18...